Indications for: NETSPOT
For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs).
Adults and Children:
See full labeling. Give 2MBq/kg (0.054mCi/kg) up to 200MBq (5.4mCi), as a single IV bolus inj. Starting 40–90mins after IV inj, acquire PET image. The effective radiation dose from 150MBq (4.05mCi) dose is 3.15mSv (to an adult weighing 75kg).
Risk of radiation exposure. Ensure adequate hydration. Should only be used by trained and experienced physicians in the safe use and handling of radionuclides to minimize radiation exposure. Avoid contact with infants, pregnant women during first 12hrs after administration. Risk for image misinterpretation and other errors. Pregnancy. Nursing mothers: interrupt for 12hrs after Netspot exposure.
Radioactive diagnostic agent.
Concomitant long-acting somatostatin analogs: image with Netspot PET just prior to analog dosing. Concomitant short-acting somatostatin analogs: may be used up to 24hrs prior to imaging with Netspot. May result in false negative imaging with high doses of repeated glucocorticoid administration.
Nausea, vomiting, inj site pain, burning sensation; hypersensitivity reactions.
Generic Drug Availability:
Single-dose kit—1 (reaction vial w. lyophilized pwd + buffer vial)